相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation
Benjamin Goldenson et al.
BLOOD (2015)
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Kelly M. Zullo et al.
CLINICAL CANCER RESEARCH (2015)
Co-inhibition of polo-like kinase 1 and aurora kinases promotes mitotic catastrophe
Jingjing Li et al.
ONCOTARGET (2015)
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
Antonino Maria Sparta et al.
CELL CYCLE (2014)
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-2013)
Chun Hei Antonio Cheung et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A. Matulonis et al.
EUROPEAN JOURNAL OF CANCER (2013)
ENMD-2076 for hematological malignancies
Jonathan How et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors
Jennifer R. Diamond et al.
CLINICAL CANCER RESEARCH (2011)
ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Graham C. Fletcher et al.
MOLECULAR CANCER THERAPEUTICS (2011)
High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia
Antonio R. Lucena-Araujo et al.
LEUKEMIA RESEARCH (2011)
Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process
Larissa Lordier et al.
BLOOD (2010)
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
A. S. Moore et al.
LEUKEMIA (2010)
PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2
Yukiko Aikawa et al.
NATURE MEDICINE (2010)
Aurora-A kinase: a novel target of cellular immunotherapy for leukemia
Toshiki Ochi et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
Kensuke Kojima et al.
BLOOD (2008)
Aurora kinases as anticancer drug targets
Oliver Gautschi et al.
CLINICAL CANCER RESEARCH (2008)
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
Elisabeth Walsby et al.
HAEMATOLOGICA (2008)
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Xue-Fei Huang et al.
BLOOD (2008)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia
Takayuki Ikezoe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations
S Chow et al.
CYTOMETRY PART A (2005)
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
S Zhao et al.
LEUKEMIA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu et al.
BLOOD (2003)
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
A Aguayo et al.
CANCER (2002)
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
T Padró et al.
LEUKEMIA (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells
ZQ Ning et al.
BLOOD (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
S Dias et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
